Global Ankylosing Spondylitis Market 2015-2019: Key Vendors are Abbvie, Amgen, Janssen Pharmaceuticals, Merck & Co and Pfizer
DUBLIN, Jan. 29, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/w8tp5p/global_ankylosing) has announced the addition of the "Global Ankylosing Spondylitis Market 2015-2019" report to their offering.
Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen.
According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.
The analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis.
The dominance of the market by biologics for the treatment of patients suffering from ankylosing spondylitis is one key trend in the market. Biologics are expected to be a preferred treatment option among the medical fraternity, patients, and the families of patients during the forecast period. This increases the number of treatment-seeking patients, which increases the overall consumption of medicines.
According to the report, presence of high unmet needs in terms of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, and the drugs have a low safety profile, resulting in a rate high mortality. Therefore, drugs that can cause disease remission in patients and have a high safety profile are expected to drive the growth of the market.
Further, the report states that expiry of patents is one of the major challenges hindering the growth of the market. Loss of patents of major drugs used in treatment of ankylosing spondylitis is expected to lower their revenue share, leading to a decrease in the overall revenue of the vendors in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Disease Overview
07. Market Landscape
08. Market Segmentation by Mechanism of Action
09. Market Segmentation by Type of Molecule
10. Market Segmentation by Route of Administration
11. Market Segmentation by Dosage Forms
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Pipeline Portfolio
22. Key Vendor Analysis
23. Other Reports in this Series
Companies Mentioned:
- Abbvie
- Amgen
- Janssen Pharmaceuticals
- Merck & Co.
- Pfizer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celltrion
- Eisai
- F. Hoffmann-La Roche
- Merck Sharp & Dohme
- Novartis
- Otsuka Pharmaceutical
- Regeneron Pharmaceuticals
- Sanofi
- ShanghaiPharmaceuticals
- UCB
For more information visit http://www.researchandmarkets.com/research/w8tp5p/global_ankylosing
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article